These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 11493473)
1. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blazar BR; Krieg AM; Taylor PA Blood; 2001 Aug; 98(4):1217-25. PubMed ID: 11493473 [TBL] [Abstract][Full Text] [Related]
2. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. Wang H; Rayburn E; Zhang R Curr Pharm Des; 2005; 11(22):2889-907. PubMed ID: 16101444 [TBL] [Abstract][Full Text] [Related]
3. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297 [TBL] [Abstract][Full Text] [Related]
4. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. Ballas ZK; Rasmussen WL; Krieg AM J Immunol; 1996 Sep; 157(5):1840-5. PubMed ID: 8757300 [TBL] [Abstract][Full Text] [Related]
5. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. Pawlowska AB; Hashino S; McKenna H; Weigel BJ; Taylor PA; Blazar BR Blood; 2001 Mar; 97(5):1474-82. PubMed ID: 11222396 [TBL] [Abstract][Full Text] [Related]
6. T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells. Hofmann C; Dunger N; Grunwald N; Hämmerling GJ; Hoffmann P; Schölmerich J; Falk W; Obermeier F Gut; 2010 Oct; 59(10):1347-54. PubMed ID: 20732920 [TBL] [Abstract][Full Text] [Related]
7. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. Hartmann G; Weeratna RD; Ballas ZK; Payette P; Blackwell S; Suparto I; Rasmussen WL; Waldschmidt M; Sajuthi D; Purcell RH; Davis HL; Krieg AM J Immunol; 2000 Feb; 164(3):1617-24. PubMed ID: 10640783 [TBL] [Abstract][Full Text] [Related]
8. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia. Wang J; Zhang W; He A; Zhao W; Cao X Oncol Rep; 2011 Feb; 25(2):519-29. PubMed ID: 21165566 [TBL] [Abstract][Full Text] [Related]
9. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Carpentier AF; Chen L; Maltonti F; Delattre JY Cancer Res; 1999 Nov; 59(21):5429-32. PubMed ID: 10554011 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Gramzinski RA; Doolan DL; Sedegah M; Davis HL; Krieg AM; Hoffman SL Infect Immun; 2001 Mar; 69(3):1643-9. PubMed ID: 11179339 [TBL] [Abstract][Full Text] [Related]
11. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435 [TBL] [Abstract][Full Text] [Related]
12. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. Ballas ZK; Krieg AM; Warren T; Rasmussen W; Davis HL; Waldschmidt M; Weiner GJ J Immunol; 2001 Nov; 167(9):4878-86. PubMed ID: 11673492 [TBL] [Abstract][Full Text] [Related]
13. The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs. Bjersing JL; Eriksson K; Tarkowski A; Collins LV Inflammation; 2004 Feb; 28(1):39-51. PubMed ID: 15072229 [TBL] [Abstract][Full Text] [Related]
14. Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. Seif AE; Barrett DM; Milone M; Brown VI; Grupp SA; Reid GS Blood; 2009 Sep; 114(12):2459-66. PubMed ID: 19636062 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation. De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252 [TBL] [Abstract][Full Text] [Related]
16. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody. Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112 [TBL] [Abstract][Full Text] [Related]
17. Cytosine-Phosphorothionate-Guanine Oligodeoxynucleotides Exacerbates Hemophagocytosis by Inducing Tumor Necrosis Factor-Alpha Production in Mice after Bone Marrow Transplantation. Liu J; Guo YM; Onai N; Ohyagi H; Hirokawa M; Takahashi N; Tagawa H; Ubukawa K; Kobayashi I; Tezuka H; Minamiya Y; Ohteki T; Sawada K Biol Blood Marrow Transplant; 2016 Apr; 22(4):627-636. PubMed ID: 26740374 [TBL] [Abstract][Full Text] [Related]
18. Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells. Lenert P; Rasmussen W; Ashman RF; Ballas ZK DNA Cell Biol; 2003 Oct; 22(10):621-31. PubMed ID: 14611683 [TBL] [Abstract][Full Text] [Related]
19. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides. Yu C; An M; Li M; Liu H Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452 [TBL] [Abstract][Full Text] [Related]
20. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Taylor PA; Ehrhardt MJ; Lees CJ; Panoskaltsis-Mortari A; Krieg AM; Sharpe AH; Murphy WJ; Serody JS; Hemmi H; Akira S; Levy RB; Blazar BR Blood; 2008 Oct; 112(8):3508-16. PubMed ID: 18614760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]